.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,943,166

« Back to Dashboard
Patent 6,943,166 protects CIALIS and is included in one NDA. There have been two Paragraph IV challenges on Cialis. There are four tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has ninety-five patent family members in forty-seven countries.

Summary for Patent: 6,943,166

Title: Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Abstract:The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
Inventor(s): Pullman; William Ernest (Far Hills, NJ), Whitaker; John Steven (Woodinville, WA)
Assignee: Lilly ICOS LLC. (Wilmington, DE)
Application Number:10/031,556
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 10th percentile
Forward Citations: 3rd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-004Jan 7, 2008RXNo6,943,166► subscribe TREATMENT OF ERECTILE DYSFUNCTION
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-001Nov 21, 2003RXNo6,943,166► subscribe TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
Lilly
CIALIS
tadalafil
TABLET;ORAL021368-001Nov 21, 2003RXNo6,943,166► subscribe TREATMENT OF ERECTILE DYSFUNCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,943,166

PCT Information
PCT FiledApril 26, 2000PCT Application Number:PCT/US00/11129
PCT Publication Date:November 09, 2000PCT Publication Number: WO00/66099

Non-Orange Book Patents for Patent: 6,943,166

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,451,807 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,943,166

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria251908► subscribe
Australia2004201988► subscribe
Australia3012900► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc